{"disease":{"id":"metastatic-hormone-sensitive-prostate-cancer","name":"metastatic hormone sensitive prostate cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT07344779","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07406282","title":"A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02799602","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1306,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04191096","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1251,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02677896","title":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1150,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT05381311","title":"Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1020,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07223372","title":"An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT00309985","title":"Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":790,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT06874114","title":"An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06334120","title":"An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05649943","title":"Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment","phase":"NA","overall_status":"RECRUITING","enrollment_count":566,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT04115007","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05901649","title":"A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":504,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT07395804","title":"How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07333066","title":"Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD","has_results":false},{"nct_id":"NCT05818683","title":"A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07451002","title":"A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France","phase":"","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Janssen Cilag S.A.S.","has_results":false},{"nct_id":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":223,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07005154","title":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":218,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT04934722","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04076059","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Astellas Pharma China, Inc.","has_results":true},{"nct_id":"NCT05717660","title":"APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Careggi","has_results":false},{"nct_id":"NCT06019676","title":"Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT07428642","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06134271","title":"Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Jianbin Bi","has_results":false},{"nct_id":"NCT07190300","title":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":155,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06991556","title":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03879122","title":"A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":135,"lead_sponsor_name":"Spanish Oncology Genito-Urinary Group","has_results":false},{"nct_id":"NCT07268794","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06498921","title":"An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care","phase":"","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07181122","title":"Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT05720130","title":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"AdvanCell Pty Limited","has_results":false},{"nct_id":"NCT06010914","title":"A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06661122","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05956639","title":"Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03899467","title":"The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":true},{"nct_id":"NCT07140900","title":"Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06452212","title":"Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT06479187","title":"PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03532217","title":"Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06312670","title":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Pedro Barata, MD, MSc","has_results":false},{"nct_id":"NCT07339267","title":"A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT04712396","title":"A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05683964","title":"Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT03343977","title":"Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Peng Wang, MD PhD","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}